Research library

Key finding

Across two randomized phase 3 trials, bremelanotide significantly improved sexual desire and reduced related distress in premenopausal women with hypoactive sexual desire disorder.

Key finding

A systematic review found heterogeneous, context-dependent associations between oxytocin measures and human sexual behaviour.

Key finding

This review links bremelanotide's effects to central melanocortin-4 receptor pathways involved in sexual desire and arousal.

Key finding

In rhesus macaques, labelled oxytocin delivered intranasally or intravenously entered cerebrospinal fluid, while administration did not trigger a measurable rise in endogenous oxytocin.

Key finding

Across female-rat models, bremelanotide increased solicitation and other centrally mediated sexual behaviours through defined melanocortin pathways.

Key finding

The study reports that administration of PT-141 to rats and nonhuman primates results in penile erections.

Key finding

The study reports that investigating intranasal oxytocin's efficacy, safety, and mechanisms as an anti-obesity medication will advance the search for optimal treatment strategies for obesity and its associated severe sequelae.

Key finding

The study reports that articles were selected that involved human participants with various psychiatric disorders and that either compared oxytocin biology to healthy controls or examined the effects of exogenous oxytocin administration.

Key finding

The study reports that many more shall be seen in the times to come.

Key finding

This preliminary evaluation suggests the potential for bremelanotide to positively affect desire and arousal in women with female sexual arousal disorder and indicates that bremelanotide is a promising candidate for further evaluation in an at-home study.

Key finding

PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra.

Key finding

Intranasal oxytocin has been shown to promote social functioning and has recently been applied as a treatment for autism spectrum disorders (ASD).

Key finding

Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD).

Key finding

Recent studies have suggested oxytocin as a possible drug to treat social deficits caused by autism spectrum disorder (ASD), but the safety of intranasal oxytocin in autistic patients has not been established.

Key finding

During the 52-week open-label extension of RECONNECT, no new safety signals were observed, and premenopausal women treated with bremelanotide exhibited sustained improvements in hypoactive sexual desire disorder symptoms.

Key finding

In total, 14 articles were included that reported on 1504 people living with pain.

Key finding

Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty.

Key finding

Schizophrenia is a form of mental disorder that is behaviorally characterized by abnormal behavior, such as social function deficits or other behaviors that are disconnected from reality.

Key finding

Unresolved inflammation represents a central feature of different human pathologies including neuropsychiatric, cardiovascular, and metabolic diseases.

Key finding

This placebo-controlled trial of intranasal oxytocin therapy in children and adolescents with autism spectrum disorder showed no significant between-group differences in the least-squares mean change from baseline on measures of social or cognitive functioning over a period of 24 weeks. (Funded by the National Institut.